DE68924155D1 - Verfahren zur herstellung von natürlichem hiv-glykoprotein 160. - Google Patents

Verfahren zur herstellung von natürlichem hiv-glykoprotein 160.

Info

Publication number
DE68924155D1
DE68924155D1 DE68924155T DE68924155T DE68924155D1 DE 68924155 D1 DE68924155 D1 DE 68924155D1 DE 68924155 T DE68924155 T DE 68924155T DE 68924155 T DE68924155 T DE 68924155T DE 68924155 D1 DE68924155 D1 DE 68924155D1
Authority
DE
Germany
Prior art keywords
producing natural
hiv glycoprotein
natural hiv
glycoprotein
iii451
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68924155T
Other languages
English (en)
Other versions
DE68924155T2 (de
Inventor
Mangalasseril Sarngadharan
Vaniambadi Kalyanaraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo NV
Original Assignee
Akzo NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo NV filed Critical Akzo NV
Application granted granted Critical
Publication of DE68924155D1 publication Critical patent/DE68924155D1/de
Publication of DE68924155T2 publication Critical patent/DE68924155T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Element Separation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physical Vapour Deposition (AREA)
DE68924155T 1988-08-16 1989-08-10 Verfahren zur herstellung von natürlichem hiv-glykoprotein 160. Expired - Lifetime DE68924155T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23285988A 1988-08-16 1988-08-16
US07/362,548 US5116740A (en) 1988-08-16 1989-06-07 Method for producing native hiv gp160
PCT/US1989/003428 WO1990002196A1 (en) 1988-08-16 1989-08-10 Method for producing native hiv gp160

Publications (2)

Publication Number Publication Date
DE68924155D1 true DE68924155D1 (de) 1995-10-12
DE68924155T2 DE68924155T2 (de) 1996-04-18

Family

ID=26926401

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924155T Expired - Lifetime DE68924155T2 (de) 1988-08-16 1989-08-10 Verfahren zur herstellung von natürlichem hiv-glykoprotein 160.

Country Status (10)

Country Link
US (1) US5116740A (de)
EP (1) EP0394386B1 (de)
KR (1) KR900702045A (de)
AT (1) ATE127526T1 (de)
AU (1) AU638214B2 (de)
DE (1) DE68924155T2 (de)
DK (1) DK175733B1 (de)
FI (1) FI102684B1 (de)
HK (1) HK1000969A1 (de)
WO (1) WO1990002196A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254457A (en) * 1989-01-11 1993-10-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies and method for identifying different aids-related viruses
ATE125157T1 (de) * 1990-04-03 1995-08-15 Genentech Inc Methoden und zusammensetzungen zur impfung gegen hiv.
US7041293B1 (en) 1990-04-03 2006-05-09 Genentech, Inc. HIV env antibodies
WO1992006220A1 (en) * 1990-10-05 1992-04-16 President And Fellows Of Harvard College Detection and isolation of ligands
NZ267838A (en) 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
US5736317A (en) * 1995-03-07 1998-04-07 Akzo Nobel N.V. Human T-cell line infected with HIV-2 which secretes a protein corresponding to native HIV-2 gp160 in an extracellular medium
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US20020155120A1 (en) * 1996-07-10 2002-10-24 Lowell George H. Protein and peptide vaccines for inducing mucosal immunity
CN1500806B (zh) * 2002-11-14 2010-05-05 上海科华生物工程股份有限公司 一种HIV－1ɡp160膜蛋白及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699785A (en) * 1984-09-18 1987-10-13 The Regents Of The University Of California Cell line producing feline leukemia virus
WO1990002567A1 (en) * 1988-09-02 1990-03-22 The Ohio State University Research Foundation Virus-derived antigenic composition and its preparation and use

Also Published As

Publication number Publication date
ATE127526T1 (de) 1995-09-15
DK175733B1 (da) 2005-02-07
WO1990002196A1 (en) 1990-03-08
EP0394386A1 (de) 1990-10-31
US5116740A (en) 1992-05-26
FI102684B (fi) 1999-01-29
KR900702045A (ko) 1990-12-05
AU4068789A (en) 1990-03-23
AU638214B2 (en) 1993-06-24
EP0394386A4 (en) 1991-03-13
DK90090D0 (da) 1990-04-10
FI102684B1 (fi) 1999-01-29
FI901879A0 (fi) 1990-04-12
DE68924155T2 (de) 1996-04-18
DK90090A (da) 1990-04-10
EP0394386B1 (de) 1995-09-06
HK1000969A1 (en) 1998-05-15

Similar Documents

Publication Publication Date Title
GR3015269T3 (en) Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type I (HIV-1) GP120 and methods of use.
ATE192653T1 (de) Anwendungen von acemannan
ATE305033T1 (de) Nanokristalline zubereitungen von menschlichen immunschwächevirus (hiv)-protease-in-hibitoren unter verwendung von cellulose- oberflächenstabilisatoren und verfahren zu deren herstellung
DE68924155D1 (de) Verfahren zur herstellung von natürlichem hiv-glykoprotein 160.
AU3332089A (en) Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
ATE103982T1 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE3174765D1 (en) High titer production of hepatitis a virus
DE3260046D1 (en) Method of producing hepatitis b surface antigen
AU2567888A (en) Hiv peptides and methods for detection of hiv
ATE123523T1 (de) Expression von hiv1- und 2- polypeptiden und deren verwendung.
GR3018918T3 (en) Artificial viral envelopes
AU7512287A (en) Expression of human t-cell lymphotropic virus (htlv-iii)reve rse transcriptase and uses thereof
DK135588A (da) Inaktivering af hiv i proteinholdige oploesninger ved hjaelp af phenoler
NL300073I1 (nl) Vaccin.
DE68908843D1 (de) Verfahren zur Herstellung von 4,6-Dimethyl-7-hydroxynonan-3-on.
ZA913909B (en) Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type i(hiv-1)gpl20 and methods of use
ZA893085B (en) Human immunodeficiency virus(hiv)env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
ATE121135T1 (de) Verfahren zur herstellung eines regulationsproteins (nef) von hiv-1 unter verwendung der humanen zellinie th4-7-5.
BG46747A3 (en) Method for preparing of 1, 5- benzothiazepine derivatives
DE68905875D1 (de) Anti-hiv-wirkung von bu-3608.
ATE76302T1 (de) Verwendung von einer immunstimulanten biologisten substanz zur herstellung eines medikaments zur behandlung des menschlichen immunschwaechevirus.
SU1473286A1 (ru) Способ получения 1,1,1-триэтоксигептана

Legal Events

Date Code Title Description
8364 No opposition during term of opposition